Systemic Therapy for Patients With Pancreatic Cancer: Current Approaches and Opportunities for Novel Avenues Toward Precision Medicine

IF 4.3 3区材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC ACS Applied Electronic Materials Pub Date : 2023-03-01 DOI:10.1016/j.clcc.2022.11.001

Ruveyda Ayasun , Turcin Saridogan , Ola Gaber , Ibrahim Halil Sahin

{"title":"Systemic Therapy for Patients With Pancreatic Cancer: Current Approaches and Opportunities for Novel Avenues Toward Precision Medicine","authors":"Ruveyda Ayasun , Turcin Saridogan , Ola Gaber , Ibrahim Halil Sahin","doi":"10.1016/j.clcc.2022.11.001","DOIUrl":null,"url":null,"abstract":"<div>Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with a 5-year overall survival of 11%. The disease is usually diagnosed at advanced stages, and systemic chemotherapy is the standard-of-care treatment for the majority of patients with PDAC. Although novel treatment options, such as targeted therapy and immunotherapy, have achieved substantial progress leading to practice-changing results, with FDA approvals for several solid tumors so far, the progress achieved for PDAC is relatively limited. Recent studies uncovered potential therapeutic targets for patients with PDAC, and potential therapeutic opportunities are currently being further examined. Herein, we review recent advances in systemic therapy regimens, including cytotoxic agents, targeted therapies, immunotherapy, and novel therapeutic options for managing patients with PDAC. We also elaborate on molecular profiling to guide treatment and existing therapeutic opportunities that may further advance the clinical care of patients with this devastating disease.</div>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1533002822001098","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}

引用次数: 2

Abstract

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with a 5-year overall survival of 11%. The disease is usually diagnosed at advanced stages, and systemic chemotherapy is the standard-of-care treatment for the majority of patients with PDAC. Although novel treatment options, such as targeted therapy and immunotherapy, have achieved substantial progress leading to practice-changing results, with FDA approvals for several solid tumors so far, the progress achieved for PDAC is relatively limited. Recent studies uncovered potential therapeutic targets for patients with PDAC, and potential therapeutic opportunities are currently being further examined. Herein, we review recent advances in systemic therapy regimens, including cytotoxic agents, targeted therapies, immunotherapy, and novel therapeutic options for managing patients with PDAC. We also elaborate on molecular profiling to guide treatment and existing therapeutic opportunities that may further advance the clinical care of patients with this devastating disease.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

癌症胰腺癌患者的系统治疗：精确医学新途径的现状和机遇

胰腺导管腺癌（PDAC）预后不佳，5年总生存率为11%。这种疾病通常在晚期被诊断出来，全身化疗是大多数PDAC患者的标准护理治疗。尽管靶向治疗和免疫疗法等新的治疗方案已经取得了实质性进展，导致了改变实践的结果，但到目前为止，随着美国食品药品监督管理局对几种实体瘤的批准，PDAC的进展相对有限。最近的研究揭示了PDAC患者的潜在治疗靶点，目前正在进一步研究潜在的治疗机会。在此，我们回顾了系统治疗方案的最新进展，包括细胞毒性药物、靶向治疗、免疫疗法和治疗PDAC患者的新选择。我们还详细介绍了分子图谱，以指导治疗和现有的治疗机会，这些机会可能会进一步推进这种毁灭性疾病患者的临床护理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊